Pembrolizumab Enters the Adjuvant Setting for Resected Stage II to IIIB NSCLC
The phase 3 ALCHEMIST treatment trial is testing whether pembrolizumab can improve outcomes when added to standard platinum-based chemotherapy after surgery for non-small cell lung cancer. The study is built around a common postoperative problem in thoracic oncology: even after complete resection, stage IIA, IIB, IIIA, and IIIB disease can recur because microscopic residual tumor cells survive initial local therapy and later re-expand under immune pressure. By pairing cytotoxic chemotherapy with PD-1 blockade, investigators are trying to push disease control beyond the limits of surgery alone.
The trial is open across the United States and is listed as recruiting. Enrollment is estimated at 1,210 participants, with an actual start date of 2020-06-16 and estimated primary completion and study completion in 2030.
Two Active Strategies, One Core Question About Disease-Free Survival
The primary endpoint is disease-free survival in patients with stage IIA-IIIB (T3-4N2) non-small cell lung cancer, comparing Arm B with Arm C. Both arms begin with one of four acceptable platinum-doublet regimens chosen by the treating physician: cisplatin plus pemetrexed, carboplatin plus pemetrexed, cisplatin plus gemcitabine hydrochloride, or carboplatin plus paclitaxel. Each regimen is delivered every 21 days for four cycles, provided there is no disease progression or unacceptable toxicity.
From there, the two strategies diverge. In Arm B, pembrolizumab begins after the chemotherapy phase as continuance therapy. In Arm C, pembrolizumab is integrated earlier, given with chemotherapy during the initial treatment phase and then continued afterward. The trial is not just asking whether checkpoint blockade should be used; it is asking when immune therapy should be introduced in relation to chemotherapy. In a disease where recurrence risk is driven by hidden residual clones, sequencing may influence how effectively the immune system can recognize tumor antigens exposed by chemotherapy-induced cell death.
Why the Timing of Pembrolizumab Could Matter Biologically
The rationale for this design is straightforward and biologically plausible. Platinum-based chemotherapy can reduce tumor burden and may increase antigen release from dying tumor cells. PD-1 inhibition with pembrolizumab can then release an immune brake, allowing T cells to attack remaining malignant cells that escaped surgery and adjuvant cytotoxic therapy. Giving the two treatments together may create a different immune context than waiting until chemotherapy is completed, especially if early tumor-antigen exposure and T-cell activation strengthen one another.
A single clinical detail makes the question sharper: Arm C exposes patients to pembrolizumab during the same 21-day cycles as chemotherapy, while Arm B delays the checkpoint inhibitor until after the platinum doublet phase. The protocol is designed to determine whether that difference in sequencing translates into longer disease control and better survival without an unacceptable increase in toxicity.
Survival, Toxicity, and Quality of Life Are Measured Side by Side
Overall survival is the main secondary efficacy endpoint, alongside adverse event rates and treatment discontinuation because of adverse events. The study also compares adverse event rates for Arms B and C with Arm A, which was closed as of Update #7 on 2/1/2022. Arm A consisted of chemotherapy followed by observation, and the protocol includes estimates of DFS and OS in that earlier cohort. A further secondary analysis examines outcomes in patients who receive at least two cycles of initial adjuvant chemotherapy, reflecting the practical reality that early discontinuation can complicate interpretation of adjuvant benefit.
Quality of life is embedded directly into the protocol rather than treated as an afterthought. Patient-reported outcomes are collected with the EORTC QLQ-C30 one year after randomization and again at completion of chemotherapy. The trial also tracks longitudinal dyspnea and coughing using the EORTC QLQ-Lung Cancer module. Those symptoms matter in resected lung cancer, where postoperative recovery, treatment fatigue, and pulmonary toxicity can influence whether a patient tolerates prolonged systemic therapy.
The study includes echocardiography when clinically indicated during screening and on trial, along with MRI, CT imaging, and blood sample collection throughout follow-up. After treatment ends, patients are assessed at 6 weeks, then every 3 months for 2 years from randomization, every 6 months for years 2-4, and annually for up to 10 years. Long follow-up is essential here because postoperative relapse in lung cancer can arrive late, and delayed immune-related toxicity can also emerge after therapy has stopped.
Biomarker Subgroups May Clarify Who Benefits Most
Correlative science is built into the study design, with subgroup analyses planned by PD-L1 status and tumor mutational burden. Patients with PD-L1 expression at least 1% are separated from those below that threshold, and tumor mutational burden is divided into high and low groups. These analyses are clinically relevant because both markers may influence response to PD-1 inhibition, although neither guarantees benefit in an individual patient. In resected disease, biomarker selection has to be interpreted against a backdrop of minimal residual disease, postoperative immune recovery, and the effects of prior chemotherapy on the tumor microenvironment.
The study population spans stage II and stage IIIA or IIIB resected non-small cell lung cancer, including squamous and non-squamous histologies. Acceptable chemotherapy backbones reflect standard thoracic oncology practice and allow the protocol to fit a range of clinical scenarios rather than forcing a single regimen. That flexibility may improve real-world applicability, but it also introduces heterogeneity that can complicate comparisons between participants.
What This Trial Can and Cannot Answer Yet
No results are posted in the record. The study remains a live test of whether adjuvant immunotherapy should follow chemotherapy or begin alongside it in surgically resected stage II to IIIB non-small cell lung cancer. Until outcomes mature, the protocol itself is the clearest signal of the field’s current priority: preventing recurrence after surgery by extending systemic control into the postoperative window, where visible disease has been removed but the biologic threat often remains.
What the trial will not do is eliminate the need for careful selection, toxicity monitoring, and long-term surveillance. The central question is whether earlier exposure to pembrolizumab can improve disease-free survival enough to justify its added complexity in patients already recovering from major lung surgery and platinum-based chemotherapy.